Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Reports Third Quarter 2015 Financial Results and Recent Highlights
November 09, 2015 16:05 ET | Calithera Biosciences, Inc.
-Single Agent Solid Tumor Clinical Benefit Seen With Tumor Metabolism Inhibitor CB-839 -Continued Signs of Activity, Tolerability, and Durability -First Preclinical Data Presented For...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera to Present New Phase 1 Solid Tumor Dose Expansion Data of CB-839 at the 2015 AACR-NCI-EORTC International Conference
November 08, 2015 12:15 ET | Calithera Biosciences, Inc.
- Single Agent Solid Tumor Clinical Benefit Seen With Tumor Metabolism Inhibitor CB-839  - Continued Signs of Activity, Tolerability, and Durability SOUTH SAN FRANCISCO, Calif., Nov. 08,...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Presents Preclinical Study Findings for CB-1158 at the 2015 AACR-NCI-EORTC International Conference
November 06, 2015 09:00 ET | Calithera Biosciences, Inc.
Potential to Combine With Anti-CTLA-4, Anti-PD-1 and Other Immuno-Oncology TherapiesIND Filing Remains on Track for 1H2016 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2015 (GLOBE NEWSWIRE) -- ...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Announces Multiple Abstracts Selected for Presentation at the 57th American Society of Hematology Annual Meeting
November 05, 2015 09:06 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), announced today that four abstracts highlighting the potential of CB-839, the Company’s...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences to Report Third Quarter 2015 Financial Results on Monday, November 9, 2015
October 30, 2015 08:00 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Announces Multiple Abstracts Selected for Presentation at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 26, 2015 17:08 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Appoints Sunil Agarwal, M.D., to Its Board of Directors
September 30, 2015 09:05 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences to Present at the Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
September 23, 2015 09:05 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences to Participate in Two Healthcare Conferences in September
September 02, 2015 09:00 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Reports Second Quarter 2015 Financial Results and Recent Highlights
August 10, 2015 16:02 ET | Calithera Biosciences, Inc.
First Clinical Data on Glutaminase Inhibitor CB-839 in Solid and Hematologic Malignancies Immuno-oncology Program with Arginase Inhibitor CB-1158 on Track for Preclinical Data Release in Fourth...